Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 3/20 | 0.58 |
| ▸ | CASP3 | P42574 | 2/20 | 0.55 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.55 |
| ▸ | TLR2 | O60603 | 2/20 | 0.52 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3436129 | 1.00 | MDM4 (0.58) | MDM4TP53CASP3SLC17A5TLR2 | |
| SCHEMBL29400770 | 1.00 | MDM4 (0.58) | MDM4TP53CASP3SLC17A5TLR2 | |
| SCHEMBL19661184 | 0.92 | TLR2 (0.58) | MDM4TP53CASP3SLC17A5TLR2 | |
| SCHEMBL9288118 | 0.91 | KMT2A (0.51) | MDM4TP53CASP3SLC17A5MDM2 | |
| SCHEMBL14432835 | 0.91 | MDM4 (0.59) | MDM4TP53CASP3SLC17A5TLR2 | |
| SCHEMBL14788958 | 0.91 | MDM4 (0.59) | MDM4TP53CASP3SLC17A5TLR2 | |
| SCHEMBL800305 | 0.89 | FDFT1 (0.57) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL1486194 | 0.89 | SLC17A5 (0.58) | MDM4TP53CASP3SLC17A5TLR2 | |
| SCHEMBL4600701 | 0.89 | FDFT1 (0.57) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL800035 | 0.89 | FDFT1 (0.57) | MDM4TP53CASP3TLR2MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10022422-B2 | Peptidomimetic macrocycles | Alleron Therapeutics, Inc. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170349638-A1 | COMPANION DIAGNOSTIC TOOL FOR PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| US-20170299576-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-10-19 | — | — | US | disclosed |
| US-20170296620-A1 | BIS-SULFHYDRYL MACROCYCLIZATION SYSTEMS | AILERON THERAPEUTICS, INC. | 2017-10-19 | — | — | US | disclosed |
| US-20170296620-A1 | BIS-SULFHYDRYL MACROCYCLIZATION SYSTEMS | AILERON THERAPEUTICS, INC. | 2017-10-19 | — | — | US | disclosed |
| US-20170298099-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-10-19 | — | — | US | disclosed |
| WO-2017165299-A2 | COMPANION DIAGNOSTIC TOOL FOR PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2017-09-28 | — | — | WO | disclosed |
| US-20170266254-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-09-21 | — | — | US | disclosed |
| US-20170266254-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-09-21 | — | — | US | disclosed |
| US-20170212125-A1 | PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES | AILERON THERAPEUTICS, INC. | 2017-07-27 | — | — | US | disclosed |
| US-20100298201-A1 | PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES | AILERON THERAPEUTICS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100184628-A1 | BIS-SULFHYDRYL MACROCYCLIZATION SYSTEMS | AILERON THERAPEUTICS, INC., A DELAWARE CORPORATION (US) | 2010-07-22 | — | — | US | disclosed |
| EP-2147925-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | MIGENIX INC. (CA) | 2010-01-27 | — | — | EP | disclosed |
| US-20090326192-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090275519-A1 | Therapeutic peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090088553-A1 | Bis-Sulfhydryl Macrocyclization Systems | AILERON THERAPEUTICS, INC., A DELAWARE CORPORATION (US) | 2009-04-02 | — | — | US | disclosed |
| US-20090047711-A1 | BIS-SULFHYDRYL MACROCYCLIZATION SYSTEMS | AILERON THERAPEUTICS, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| EP-1656390-A2 | COMPOSITIONS OF LIPOPEPTIDE ANTIBIOTIC DERIVATIVES AND METHODS OF USE THEREOF | MIGENIX INC. (CA) | 2006-05-17 | — | — | EP | disclosed |
| US-20050153876-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | MIGENIX INC. (CA) | 2005-07-14 | — | — | US | disclosed |
| WO-2005000878-A2 | COMPOSITIONS OF LIPOPEPTIDE ANTIBIOTIC DERIVATIVES AND METHODS OF USE THEREOF | MIGENIX INC. (CA) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170266254-A1 | PEPTIDOMIMETIC MACROCYCLES | TCF4, CTNNB1, WNT1 | MDM4 190/4885TP53 136/4885CASP3 670/4885 |
| US-20090326192-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | VIP, ANPEP, DNPEP | MDM4 2135/4885TP53 691/4885CASP3 909/4885 |
| US-20090088553-A1 | Bis-Sulfhydryl Macrocyclization Systems | CBS, HLCS, CTH | MDM4 3300/4885TP53 1820/4885CASP3 2522/4885 |
| US-20090047711-A1 | BIS-SULFHYDRYL MACROCYCLIZATION SYSTEMS | CBS, HLCS, CTH | MDM4 3300/4885TP53 1820/4885CASP3 2522/4885 |
| US-20170349638-A1 | COMPANION DIAGNOSTIC TOOL FOR PEPTIDOMIMETIC MACROCYCLES | TP53, TP53BP1, VHL | MDM4 10/4885TP53 1/4885CASP3 949/4885 |
| US-20050153876-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | NRDC, NOD2, NGLY1 | MDM4 2087/4885TP53 2126/4885CASP3 352/4885 |
| US-20170296620-A1 | BIS-SULFHYDRYL MACROCYCLIZATION SYSTEMS | CBS, HLCS, CTH | MDM4 3300/4885TP53 1820/4885CASP3 2522/4885 |
| US-20170212125-A1 | PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES | VIP, ANPEP, NGLY1 | MDM4 1737/4885TP53 763/4885CASP3 1759/4885 |
| US-20100184628-A1 | BIS-SULFHYDRYL MACROCYCLIZATION SYSTEMS | CBS, HLCS, CTH | MDM4 3300/4885TP53 1820/4885CASP3 2522/4885 |
| US-20170298099-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | VIP, ANPEP, DNPEP | MDM4 2135/4885TP53 691/4885CASP3 909/4885 |
| US-20100298201-A1 | PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES | VIP, ANPEP, NGLY1 | MDM4 1737/4885TP53 763/4885CASP3 1759/4885 |
| US-20170299576-A1 | PEPTIDOMIMETIC MACROCYCLES | CCL2, TAP2, TAP1 | MDM4 655/4885TP53 980/4885CASP3 1868/4885 |
| US-20090275519-A1 | Therapeutic peptidomimetic macrocycles | PCNA, MKI67, NFATC1 | MDM4 517/4885TP53 6/4885CASP3 1684/4885 |
| US-10022422-B2 | Peptidomimetic macrocycles | HAVCR2, ZC3HAV1, ZC3HAV1L | MDM4 1962/4885TP53 591/4885CASP3 1057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.